ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0392

Prevalence and Survival of Systemic Sclerosis (SSc) and Associated Interstitial Lung Disease (ILD) in Ontario, Canada over 10 Years
Abstract Number: 1719

Prevalence and Trajectory of Erosions, Synovitis, and Bone Marrow Edema in Feet of Patients with Early Rheumatoid Arthritis
Abstract Number: 1025

Prevalence Estimates for Systemic Lupus Erythematosus over Four Decades
Abstract Number: 0394

Prevalence of a Diagnosis of Osteopenia/Osteoporosis Amongst Patients with Systemic Sclerosis and Identification of Associated Clinical Factors
Abstract Number: 1426

Prevalence of ANCA-associated Vasculitis and Spatial Association with Quarries in a French Northeast Region: A Capture-recapture and Geospatial Analysis
Abstract Number: 1066

Prevalence of Cervical Dysplasia in Women with Antisynthetase Syndrome
Abstract Number: 1313

Prevalence of Extra-Articular Manifestations in Early Ankylosing Spondylitis versus Non-Radiographic Axial Spondyloarthritis: A Systematic Literature Review and Meta-Analysis of 1504 Patients
Abstract Number: 1134

Prevalence of Frailty and Associated Factors in a National Observational Cohort of Rheumatic Diseases
Abstract Number: 0009

Prevalence of Hydroxychloroquine and Chloroquine Side Effects in Rheumatology Patients: A Retrospective Survey of 115 Cases
Abstract Number: 0185

Prevalence of Migraine and Neuropathic Pain in Rheumatic Disease
Abstract Number: 1287

Prevalence of Morbidity Prior to Diagnosis of Incident Systemic Lupus Erythematosus in the Danish Population
Abstract Number: 0132

Prevalence of Osteoporosis and Fragitlity Fractures Is Not Different Between ACPA Positive Patients Compared to ACPA Negative Patients in a Real World Setting, Despite Longer Disease Duration and Glucocorticoid-Treatment
Abstract Number: 1199

Prevalence of Subclinical Interstitial Lung Disease After a Mean Rheumatoid Arthritis Duration of 13 Years: Results from the French ESPOIR Cohort
Abstract Number: 0081

Prevalence of Systemic Autoimmune Diseases in Polycystic Ovary Syndrome
Abstract Number: 0418

Prevalence of Thyroid Disease Among Patients with Vasculitis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].